1980
|
Sign up to set email alerts
Effects of Ocular Decongestants
Search citation statements
Order By: Relevance
Paper Sections
Select...
30
2
1
0
Citation Types
1
11
0
1
Year Published
Range
1980
19802026
2026Publication Types
Select...
26
6
1
Relationship
0
33
Authors
Journals
Cited by 33 publications
(13 citation statements)
References 1 publication
1
11
0
1
Order By: Relevance
Abstract
Smart CitationsHow this paper cites the one you are viewing
“…Other formulations of naphazoline or oxymetazoline followed in the next decade, and these and other topicals gained overthe-counter (in formulations with lower concentration active) status by the mid-1980s. As a group, the vasoconstrictors were effective at relieving hyperemia but did little to alleviate other symptoms [7]. In addition, these drugs are all short acting, cause significant stinging upon instillation, and are further limited by a prominent tachyphylaxis.…”
Section: The First Generation Of Ocular Allergy Therapy
supporting
confidence: 38%
Abstract
Smart CitationsHow this paper cites the one you are viewing
“…Other formulations of naphazoline or oxymetazoline followed in the next decade, and these and other topicals gained overthe-counter (in formulations with lower concentration active) status by the mid-1980s. As a group, the vasoconstrictors were effective at relieving hyperemia but did little to alleviate other symptoms [7]. In addition, these drugs are all short acting, cause significant stinging upon instillation, and are further limited by a prominent tachyphylaxis.…”
Section: The First Generation Of Ocular Allergy Therapy
supporting
confidence: 38%
Abstract
Smart CitationsHow this paper cites the one you are viewing
“…In clinical trials, histamine-induced hyperemia has been used for testing the decongestant actions of OMZ (3,7,8), yet the vasoconstrictive actions of OMZ on animals' conjunctival mucosa has not been tested so far. In this study, the vasoconstrictive action of OMZ on conjunctival mucosa induced by histamine has been confirmed (Fig 1; Table 1).…”
Section: Discussion
mentioning
confidence: 43%
Abstract
Smart CitationsHow this paper cites the one you are viewing
“…Histamine produces a dosedependent response when instilled in the eye, and thus has been used as a model for screening anti-allergic drugs. Although such an agent can help evaluate drugs with antihistaminic properties [25], and drugs that actively reduce redness, such as vasoconstrictors [26], this challenge is not directly stimulating mast-cell degranulation, as happens with allergen. Substances such as compound 48/80, which is a secretagogue that induces mast-cell degranulation, have also been used in human challenge tests [10].…”
Section: The Conjunctival Allergen Challenge Model For Studying Aller
mentioning
confidence: 44%
Abstract
Smart CitationsHow this paper cites the one you are viewing
“…Other formulations of naphazoline or oxymetazoline followed in the next decade, and these and other topicals gained overthe-counter (in formulations with lower concentration active) status by the mid-1980s. As a group, the vasoconstrictors were effective at relieving hyperemia but did little to alleviate other symptoms [7]. In addition, these drugs are all short acting, cause significant stinging upon instillation, and are further limited by a prominent tachyphylaxis.…”
Section: The First Generation Of Ocular Allergy Therapy
supporting
confidence: 38%
Abstract
Smart CitationsHow this paper cites the one you are viewing
“…In clinical trials, histamine-induced hyperemia has been used for testing the decongestant actions of OMZ (3,7,8), yet the vasoconstrictive actions of OMZ on animals' conjunctival mucosa has not been tested so far. In this study, the vasoconstrictive action of OMZ on conjunctival mucosa induced by histamine has been confirmed (Fig 1; Table 1).…”
Section: Discussion
mentioning
confidence: 43%
Abstract
Smart CitationsHow this paper cites the one you are viewing
“…Histamine produces a dosedependent response when instilled in the eye, and thus has been used as a model for screening anti-allergic drugs. Although such an agent can help evaluate drugs with antihistaminic properties [25], and drugs that actively reduce redness, such as vasoconstrictors [26], this challenge is not directly stimulating mast-cell degranulation, as happens with allergen. Substances such as compound 48/80, which is a secretagogue that induces mast-cell degranulation, have also been used in human challenge tests [10].…”
Section: The Conjunctival Allergen Challenge Model For Studying Aller
mentioning
confidence: 44%
Abstract
Smart CitationsHow this paper cites the one you are viewing
“…Other formulations of naphazoline or oxymetazoline followed in the next decade, and these and other topicals gained overthe-counter (in formulations with lower concentration active) status by the mid-1980s. As a group, the vasoconstrictors were effective at relieving hyperemia but did little to alleviate other symptoms [7]. In addition, these drugs are all short acting, cause significant stinging upon instillation, and are further limited by a prominent tachyphylaxis.…”
Section: The First Generation Of Ocular Allergy Therapy
supporting
confidence: 38%
Abstract
Smart CitationsHow this paper cites the one you are viewing
“…In clinical trials, histamine-induced hyperemia has been used for testing the decongestant actions of OMZ (3,7,8), yet the vasoconstrictive actions of OMZ on animals' conjunctival mucosa has not been tested so far. In this study, the vasoconstrictive action of OMZ on conjunctival mucosa induced by histamine has been confirmed (Fig 1; Table 1).…”
Section: Discussion
mentioning
confidence: 43%
Abstract
Smart CitationsHow this paper cites the one you are viewing
“…Histamine produces a dosedependent response when instilled in the eye, and thus has been used as a model for screening anti-allergic drugs. Although such an agent can help evaluate drugs with antihistaminic properties [25], and drugs that actively reduce redness, such as vasoconstrictors [26], this challenge is not directly stimulating mast-cell degranulation, as happens with allergen. Substances such as compound 48/80, which is a secretagogue that induces mast-cell degranulation, have also been used in human challenge tests [10].…”
Section: The Conjunctival Allergen Challenge Model For Studying Aller
mentioning
confidence: 44%